About this trial
Overall in this project, the primary goal is to evaluate the efficacy of virtual reality exposure (VRE) for adolescents with elevated social anxiety using a three-arm randomized controlled trial: (1) virtual reality exposure (VRE); (2) in vivo exposure (IVE); and (3) waitlist (WL) - the control condition.
It is predicted that both VRE and IVE will be more successful in decreasing social anxiety symptoms than the WL condition at post-assessment and that VRE will be as effective as in vivo in reducing social anxiety symptoms. Furthermore, it is expected that there will be no difference between the two active conditions in the long term (at 3- months \& 6-months follow up). Similar results are expected in the secondary outcome measures, intended to capture the participants' general well-being.
Moreover, the study has the following (secondary) objectives:
* To elucidate potential working mechanisms of VRE and IVE * To identify predictors of adolescents' response to VRE and IVE * To assess to what extent adolescents accept VRE and IVE and how they experience it
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Elevated levels of social anxiety (as per the Social Phobia Inventory; ≥ 19)
Fluent in Dutch
12-16 years old
Severe social anxiety disorder
Disqualifiers
None
Trial design
Parallel
Treatments tested in this trial
In vivo exposure
BehavioralExposure in vivo involves the confrontation with fear-evoking situations in real life.
(Virtual reality) exposure
BehavioralExposure in virtual reality involves the confrontation with fear-evoking situations which are generated by a computer using VR technology.
Treatment groups
Trial outcomes
Primary outcomes
Brief version of the Social Phobia and Anxiety Inventory (SPAI-18)
General measure of social anxiety
Liebowitz Social Anxiety Scale for Children and Adolescents (LSAS-CA) - Avoidance subscale
Avoidance measure of social anxiety
Behavioral assessment task (BAT) - Peak anxiety
Subjective units of distress (SUD) measured on a visual analogue scale (VAS); administered immediately after the BAT
Secondary outcomes
Brief Resilience Scale (BRS)
General measure of resilience
Multidimensional Adolescent Functioning Scale (MAFS) - Peer and General functioning subscales
General measure of psychosocial functioning
Revised Children's Anxiety and Depression Scale (RCADS)
General measure of depression and anxiety + Predictor
Self-Efficacy Questionnaire for Children (SEQ-C) - Social efficacy subscale
General measure of social self efficacy and mechanism
Other outcomes
Behavioral inhibition system / behavioral activation system scale (BIS/BAS)
Predictor
Experiences in Close Relationship Scale - Relationship Structures (ECR-RS)
Predictor
Immersive Tendency Questionnaire (ITQ) - Factor Involvement
Predictor
Unified Theory of Acceptance and Use of Technology (UTAUT-A) - Attitudes subscale
Predictor
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
KU Leuven
Lead sponsor
Utrecht University
Collaborator